Elsevier

Metabolism

Volume 43, Issue 2, February 1994, Pages 174-179
Metabolism

Total-body and myocardial substrate oxidation in congestive heart failure

https://doi.org/10.1016/0026-0495(94)90241-0Get rights and content

Abstract

Congestive heart failure is a condition associated with increased plasma norepinephrine levels, which have been demonstrated to impair glucose handling. In the present study, 10 patients suffering from congestive heart failure and 10 healthy age- and body mass index-matched subjects were submitted to a hyperinsulinemic (insulin infusion rate, 0.5 mU/kg · min−1) glucose clamp, while simultaneous d-3H-glucose infusion and indirect calorimetry allowed for determination of glucose turnover parameters and substrate oxidation, respectively. On a separate day, basal local (myocardial) indirect calorimetry was also performed. Our data demonstrate that in congestive heart failure, fasting myocardial glucose oxidation (Gox) was inhibited with a simultaneous increase in lipid oxidation (Lox). In our patients, a significant decrease in total-body insulin-stimulated glucose metabolism (31.0 ± 0.5 v 20.3 ± 0.4 μmol/kg · min−1, P < .01) and nonoxidative glucose metabolism (18.9 ± 1.1 v 11.0 ± 0.5 μmol/kg · min−1, P < .05) was also found. Such latter changes were also associated with a simultaneous overdrive of Lox (0.4 ± 0.2 v 1.9 ± 0.2 μmol/kg · min−1, P < .02) that was correlated with an enhanced availability of plasma free fatty acids (FFAs).

References (33)

  • PJ Randle et al.

    The glucose fatty acid cycle. Its role in insulin sensitivity and the metabolic disturbance of diabetes mellitus

    Lancet

    (1963)
  • D Wititsuwannakul et al.

    Mechanism of palmityl coenzyme A inhibition of liver glycogen synthase

    J Biol Chem

    (1977)
  • SA Blumenthal

    Stimulation of gluconeogenesis by palmitic acid in rat hepatocytes. Evidence that this effect can be dissociated from the provision of reducing equivalent

    Metabolism

    (1983)
  • BW Lassers et al.

    Relationship in man between plasma free fatty acids and myocardial metabolism of carbohydrate substrates

    Lancet

    (1971)
  • JN Cohn et al.

    Plasma norepinephrine as guide to prognosis in patients with chronic congestive heart failure

    N Engl J Med

    (1984)
  • MR Bristow

    The adrenergic nervous system in heart failure

    N Engl J Med

    (1984)
  • Cited by (154)

    • The glycolytic pathway to heart failure

      2023, Glycolysis: Tissue-Specific Metabolic Regulation in Physio-pathological Conditions
    • Cardiac energy metabolism in heart failure

      2023, Cardiovascular Endocrinology and Metabolism: Theory and Practice of Cardiometabolic Medicine
    • Identifying functional metabolic shifts in heart failure with the integration of omics data and a heart-specific, genome-scale model

      2021, Cell Reports
      Citation Excerpt :

      In the case of ketone body utilization, a recent metabolomics analysis suggests that changes in circulating levels of ketone bodies influence increased use in late-stage heart failure (Murashige et al., 2020). Although the role of fatty acids in late-stage heart failure remains controversial, with some studies measuring increased use (Paolisso et al., 1994; Taylor et al., 2001) whereas animal models measure no change (Zhabyeyev et al., 2013) or decreased use (Allard et al., 1994; Neubauer, 2007), the TIDEs analysis demonstrated no consistent change in gene expression for fatty acid oxidation in late-stage heart failure (Figures 5B and S3B). Together, this suggests that factors other than changes in transcription are driving the measured changes in metabolite uptake for ketone bodies, amino acids, and fatty acids in late-stage heart failure.

    • Ketone metabolism in the failing heart

      2020, Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids
    View all citing articles on Scopus
    View full text